Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Open-label, Single Arm, Phase III Study to Assess the Efficacy and Safety of Macitentan (ACT-064992) in Subjects With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

NCT03809650 is registered in ClinicalTrials.gov with Actelion as lead sponsor.

NCT NCT03809650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03809650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Open-label, Single Arm, Phase III Study to Assess the Efficacy and Safety of Macitentan (ACT-064992) in Subjects With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Lead sponsor
Actelion
Phase
Phase 3
Overall status
Terminated
Start date
January 8, 2019
Completion date
June 29, 2020
Enrollment
9 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

chronic thromboembolic pulmonary hypertension (cteph)